Clinical Trial Update: Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients [Phase 2]

View source ↗

Summary

Phase IIa randomized, multicenter, open-label study to identify the better intraperitoneal dose of Removab (catumaxomab) in platinum-refractory epithelial ovari…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Removab (catumaxomab)

Snippet

Sponsor: AGO Study Group | Conditions: Ovarian Cancer, Fallopian Tube Neoplasms | Phase 2 | Status: COMPLETED